HALO
Price
$46.96
Change
-$0.36 (-0.76%)
Updated
Dec 20 closing price
65 days until earnings call
PRME
Price
$2.92
Change
+$0.13 (+4.66%)
Updated
Dec 20, 04:59 PM (EDT)
75 days until earnings call
Ad is loading...

HALO vs PRME

Header iconHALO vs PRME Comparison
Open Charts HALO vs PRMEBanner chart's image
Halozyme Therapeutics
Price$46.96
Change-$0.36 (-0.76%)
Volume$4.79M
CapitalizationN/A
Prime Medicine
Price$2.92
Change+$0.13 (+4.66%)
Volume$59.31K
CapitalizationN/A
HALO vs PRME Comparison Chart
Loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
HALO vs. PRME commentary
Dec 22, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HALO is a Hold and PRME is a Hold.

COMPARISON
Comparison
Dec 22, 2024
Stock price -- (HALO: $46.96 vs. PRME: $2.92)
Brand notoriety: HALO and PRME are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HALO: 273% vs. PRME: 204%
Market capitalization -- HALO: $5.97B vs. PRME: $382.99M
HALO [@Biotechnology] is valued at $5.97B. PRME’s [@Biotechnology] market capitalization is $382.99M. The market cap for tickers in the [@Biotechnology] industry ranges from $464.4B to $0. The average market capitalization across the [@Biotechnology] industry is $2.57B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HALO’s FA Score shows that 2 FA rating(s) are green whilePRME’s FA Score has 0 green FA rating(s).

  • HALO’s FA Score: 2 green, 3 red.
  • PRME’s FA Score: 0 green, 5 red.
According to our system of comparison, HALO is a better buy in the long-term than PRME.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HALO’s TA Score shows that 5 TA indicator(s) are bullish while PRME’s TA Score has 4 bullish TA indicator(s).

  • HALO’s TA Score: 5 bullish, 3 bearish.
  • PRME’s TA Score: 4 bullish, 6 bearish.
According to our system of comparison, HALO is a better buy in the short-term than PRME.

Price Growth

HALO (@Biotechnology) experienced а -2.17% price change this week, while PRME (@Biotechnology) price change was +1.39% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -2.20%. For the same industry, the average monthly price growth was -1.27%, and the average quarterly price growth was +2.17%.

Reported Earning Dates

HALO is expected to report earnings on Feb 25, 2025.

PRME is expected to report earnings on Mar 06, 2025.

Industries' Descriptions

@Biotechnology (-2.20% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
HALO($5.97B) has a higher market cap than PRME($383M). HALO YTD gains are higher at: 27.056 vs. PRME (-67.043). HALO has higher annual earnings (EBITDA): 580M vs. PRME (-207.13M). HALO has more cash in the bank: 666M vs. PRME (176M). PRME has less debt than HALO: PRME (41.2M) vs HALO (1.5B). HALO has higher revenues than PRME: HALO (947M) vs PRME (800K).
HALOPRMEHALO / PRME
Capitalization5.97B383M1,559%
EBITDA580M-207.13M-280%
Gain YTD27.056-67.043-40%
P/E Ratio15.55N/A-
Revenue947M800K118,375%
Total Cash666M176M378%
Total Debt1.5B41.2M3,650%
FUNDAMENTALS RATINGS
HALO vs PRME: Fundamental Ratings
HALO
PRME
OUTLOOK RATING
1..100
2769
VALUATION
overvalued / fair valued / undervalued
1..100
77
Overvalued
72
Overvalued
PROFIT vs RISK RATING
1..100
33100
SMR RATING
1..100
12100
PRICE GROWTH RATING
1..100
5791
P/E GROWTH RATING
1..100
76100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

PRME's Valuation (72) in the null industry is in the same range as HALO (77) in the Biotechnology industry. This means that PRME’s stock grew similarly to HALO’s over the last 12 months.

HALO's Profit vs Risk Rating (33) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that HALO’s stock grew significantly faster than PRME’s over the last 12 months.

HALO's SMR Rating (12) in the Biotechnology industry is significantly better than the same rating for PRME (100) in the null industry. This means that HALO’s stock grew significantly faster than PRME’s over the last 12 months.

HALO's Price Growth Rating (57) in the Biotechnology industry is somewhat better than the same rating for PRME (91) in the null industry. This means that HALO’s stock grew somewhat faster than PRME’s over the last 12 months.

HALO's P/E Growth Rating (76) in the Biotechnology industry is in the same range as PRME (100) in the null industry. This means that HALO’s stock grew similarly to PRME’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HALOPRME
RSI
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
74%
Bullish Trend 2 days ago
75%
Momentum
ODDS (%)
Bearish Trend 2 days ago
69%
Bearish Trend 2 days ago
87%
MACD
ODDS (%)
Bullish Trend 2 days ago
68%
Bearish Trend 2 days ago
84%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
70%
Bullish Trend 2 days ago
81%
TrendMonth
ODDS (%)
Bullish Trend 2 days ago
75%
Bearish Trend 2 days ago
85%
Advances
ODDS (%)
Bullish Trend 5 days ago
76%
Bullish Trend 2 days ago
76%
Declines
ODDS (%)
N/A
Bearish Trend 4 days ago
87%
BollingerBands
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
72%
Aroon
ODDS (%)
N/A
Bearish Trend 2 days ago
90%
View a ticker or compare two or three
Ad is loading...
HALO
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
PRME
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
ETFs / NAMEPrice $Chg $Chg %
SUSA122.761.64
+1.35%
iShares MSCI USA ESG Select ETF
THNQ49.740.66
+1.34%
Robo Global® Artificial Intelligence ETF
DFSI32.760.01
+0.03%
Dimensional International Sstby Cr 1 ETF
NSCS28.47N/A
N/A
Nuveen Small Cap Select ETF
ISEP27.49-0.02
-0.07%
Innovator Intl Dev Pwr Bffr ETF - Sept

PRME and

Correlation & Price change

A.I.dvisor indicates that over the last year, PRME has been loosely correlated with CRSP. These tickers have moved in lockstep 63% of the time. This A.I.-generated data suggests there is some statistical probability that if PRME jumps, then CRSP could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To PRME
1D Price
Change %
PRME100%
+4.66%
CRSP - PRME
63%
Loosely correlated
+0.83%
BEAM - PRME
61%
Loosely correlated
+8.16%
NTLA - PRME
59%
Loosely correlated
+1.08%
RXRX - PRME
56%
Loosely correlated
-0.90%
ABCL - PRME
55%
Loosely correlated
+4.80%
More